MktsMarkets

Cyclerion Therapeutics, Inc.
NASDAQ: CYCNKey statistics
CYCN News
Stories mentioning CYCN from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 0.00 | 1,025 | 875.00 | 93.00 | 81.00 | 1,806 | 194.00 | 0.00 |
| Cost of Goods Sold | ||||||||
| Gross Profit | ||||||||
| Operating Expenses | ||||||||
| Research & Development | 730.00 | 519.00 | 348.00 | 56.00 | 36.00 | 56.00 | 81.00 | 105.00 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | 3,209 | 1,863 | 1,881 | 1,765 | 1,538 | 1,304 | 1,322 | 1,384 |
| Operating Income (Loss) | (3,209) | (838.00) | (1,006) | (1,672) | (1,457) | 502.00 | (1,128) | (1,384) |
| Interest Income | ||||||||
| Interest Expense | ||||||||
| Other Expense | ||||||||
| Pretax Income | ||||||||
| Tax Provision | ||||||||
| Net Income (Loss) | (3,177) | (799.00) | (976.00) | (324.00) | (1,429) | 530.00 | (723.00) | (1,322) |
| Earnings Per Share (Basic) | (0.76) | (0.25) | (0.30) | (0.11) | (0.56) | 0.21 | (0.29) | (0.53) |
| Earnings Per Share (Diluted) | (0.76) | (0.25) | (0.30) | (0.11) | (0.56) | 0.21 | (0.29) | (0.53) |
| Weighted Average Shares Outstanding (Basic) | 4,205 | 3,181 | 3,225 | 3,071 | 2,556 | 2,518 | 2,526 | 2,510 |
| Weighted Average Shares Outstanding (Diluted) | 4,205 | 3,181 | 3,225 | 3,071 | 2,556 | 2,518 | 2,526 | 2,510 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About CYCN
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) is a stock listed on the Nasdaq Stock Market under the ticker symbol CYCN. It last traded at $32.50 (Nov 16, 2026, 7:00 PM ET), down 0.6% on the day. That gives Cyclerion Therapeutics a market capitalisation of $1.5B.
Over the past 52 weeks CYCN has traded between $7.19 and $59.36.
Revenue for the quarter ended Mar 31, 2026 was $0; a net loss of $3.2M.
| Quarter ended | Revenue | Net income | Margin |
|---|---|---|---|
| Mar 31, 2026 | $0 | -$3.2M | — |
| Dec 31, 2025 | $1.0M | -$799.0K | -78.0% |
| Sep 30, 2025 | $875.0K | -$976.0K | -111.5% |
| Jun 30, 2025 | $93.0K | -$324.0K | -348.4% |
From Cyclerion Therapeutics’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…